Overall verdict
Buy
7.4/10
1-year performance
+32.38%
Score breakdown
Up 32.4% over 1 year, 77% of the 52-week range.
Strongest: Growth 10.0/10. Weakest: Shareholder return 1.7/10.
9 analysts, target +0.2% vs the price.
argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR ;
empasiprubart for MMN, delayed graft function, and CIDP ; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy. In addition, the company is developing ARGX-213, a neonatal Fc receptor (FcRn)-targeted antibody engineered for half-life extension and sustained IgG reduction ; ARGX-124, a FcRn pipeline candidate ; ARGX-109, which targets IL-6 to treat inflammation ; ARGX-121, which targets immunoglobulin A ;
and ARGX-118, which develops antibodies against Galectin-10, as well as cusatuzumab, ARGX-112, ARGX-114, and ARGX-115. It has strategic partnerships and license agreements with Zai Lab to develop and commercialize efgartigimod ; Halozyme Therapeutics to its ENHANZE for the prevention and treatment of human diseases ; OncoVerity, Inc for cusatuzumab ; and AbbVie, Inc. for ARGX-115. argenx SE was incorporated in 2008 and is based in Amsterdam, the Netherlands.
Sector
Health Care
Industry
Biotechnology
Primary listing
Euronext
Netherlands
CEO
Karen Massey
Founded
2008
Employees
1 863
Revenue / employee
2.3M USD
Next earnings
October 22, 2026
Research uses the underlying stock’s market history. The purchase quote is calculated separately when you review your order.
52-week high
925.00 EUR
52-week low
568.40 EUR
1-year performance
32.38%
Rising
Year-to-date performance
16.46%
Rising
Drawdown
-8.84%
Mild pullback
Position in the 52-week range
77% of range
Against the world ETF
Over 12 years, from July 2014 to August 2026, the share did better than the world ETF once risk is accounted for.
10,000 € placed at the end of July 2014 are worth today
| argenx | 1 054 940 € |
| World ETF | 41 136 € |
| STOXX Europe 600 | 27 090 € |
| Risk-free placement | 10 917 € |
The risk
- Shaking:the share moves 3.6 times as much as the world ETF.
- Worst fall:-39 % between July 2023 and December 2023. 10,000 € placed at the top fell to 6 074 €. The world ETF, at worst: -34 %. Back to its high in 9 months.
argenx earned 26 times as much as the world ETF since 2014
Value of 10,000 euros placed at the end of July 2014, dividends reinvested, in euros
- argenx: 1 054 940 €
- World ETF: 41 136 €
- STOXX Europe 600: 27 090 €
- Risk-free placement: 10 917 €
Share price without dividends; the world ETF and the index reinvest theirs. A dividend payer is therefore understated here.
Based on past performance. This is not a recommendation.
Range: 520.74 EUR - 563.15 EUR (comparables only)
The price implies growth of 17.98% per year; the company grows at 25.00%.
Gross margin 89.5%, net margin 32.8%, ROIC 23.3%, ROE 23.4%.
Net margin
32.82%
Exceptional
Sector -15.62%|S&P 12.97%
Gross margin
89.49%
High
Return on equity (ROE)
23.43%
High
Sector -19.73%|S&P 16.52%
Return on invested capital (ROIC)
23.31%
High
Free cash flow margin (FCF)
21.65%
High
Profit-to-cash conversion (FCF conversion)
0.66x
Fair
Margin stability
73.7 pts
Very uneven
Growth
10.0/10Revenue up 59.3% over 1 year, 152.0% a year over 5.
Revenue (trailing 12 months)
5.1Md USD
Revenue growth (1y)
59.30%
Hyper-growth
Revenue growth (3y)
841.67%
Hyper-growth
EPS growth (1y)
95.20%
Hyper-growth
EPS CAGR (5y)
—
EPS revisions (3 months)
10.90%
Sharply revised up
Valuation
4.7/10P/E 37.3x, forward P/E 31.2x, EV/EBITDA 36.1x, PEG 1.56.
P/E (TTM)
37.3x
Expensive
Sector 29.6x|S&P 23.0x
Forward P/E
31.2x
Expensive
EV / EBITDA
36.1x
Expensive
Sector 23.2x|S&P 14.5x
PEG
1.56
Expensive
Sector 0.12|S&P 0.86
Fair value (reverse DCF)
541.94 EUR
Deeply overvalued
Market cap
59.5Md USD
Financial strength
10.0/10Cash covers 11029.8% of the debt, net debt/EBITDA -4.1x.
Net debt / EBITDA
-4.1x
Net cash
Gearing (net debt / equity)
-61.03%
Net cash
Cash
5.2Md USD
Cash / market cap
8.70%
Solid
Cash / total debt
11029.79%
Net cash
Interest coverage
258.2x
Very solid
Net debt
-5.1Md USD
Equity
8.4Md USD
Closed daily candles, 2 years
Last close on September 24, 2026: 834.80 EUR
- MM20869.11
- MM50825.05
- MM200733.50
- RSI 1444.2
Top panel: closed candles, 20, 50 and 200-day moving averages, with volume in grey. Bottom panel: 14-day RSI with dashed 30 and 70 levels.
200-day average slope, 1 month
+1.24%
200-day average slope, 3 months
+4.53%
50-day average slope, 1 month
+4.50%
Price structure
Lower lows
Bullish RSI divergence
No
20-day volatility
1.42 % per day
Volatility change
-40.21%
Forecasts by fiscal year
| Fiscal year | EPS | Normalised EPS | Revenue | EBITDA | Net income |
|---|---|---|---|---|---|
| 2026 | 30.77 (2) | 29.84 (2) | 6 266 (4) | 2 011 (2) | 1 143 (3) |
| 2027 | 37.52 (3) | 36.77 (3) | 7 622 (4) | 2 604 (2) | 2 391 (4) |
Amounts in millions of USD, EPS in USD per share. In brackets, the number of analysts. Consensus as of September 22, 2026.
Same sub-industry: 431 companies behind the medians.
| # | Company | Code | Country | Overall / 10 | Fundamentals / 10 | Mkt cap | P/E | Net margin | Revenue growth | ROIC | Net debt / EBITDA | FCF yield | 1-year perf. |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | ARGX | 7.4 | 6.8 | 59.5Md USD | 37.3x | 32.8 % | 59.3 % | 23.3 % | -4.1x | 1.9 % | 32.4 % | ||
| 2 | VRTX | 6.7 | 5.9 | 131Md USD | 30.0x | 34.7 % | 12.0 % | 21.5 % | -0.9x | 2.9 % | 38.4 % | ||
| 3 | REGN | 6.6 | 6.0 | 82.6Md USD | 19.8x | 27.9 % | 16.7 % | 13.0 % | -1.3x | 4.6 % | 40.2 % | ||
| 4 | AMGN | 6.3 | 6.2 | 220Md USD | 25.2x | 22.9 % | 9.8 % | 14.0 % | 2.9x | 4.6 % | 42.2 % | ||
| 5 | ABBV | 6.2 | 5.6 | 468Md USD | 74.9x | 9.7 % | 10.2 % | 10.5 % | 2.2x | 3.9 % | 19.4 % | ||
| 6 | GILD | 5.5 | 4.3 | 188Md USD | Not meaningful (loss) | -10.6 % | 10.7 % | -8.4 % | 1.1x | 6.9 % | 31.0 % | ||
| 7 | CSL | 4.5 | 4.2 | 60.5Md USD | Not meaningful (loss) | -15.6 % | -2.8 % | -8.9 % | 1.8x | 4.7 % | -9.7 % | ||
| 8 | NTRA | 3.8 | 2.3 | 56.3Md USD | Not meaningful (loss) | -7.1 % | 37.7 % | -11.6 % | 3.9x | 0.1 % | 136.1 % | ||
| 9 | MRNA | 2.7 | 1.9 | 72.7Md USD | Not meaningful (loss) | -141.4 % | 2.1 % | -34.8 % | 1.3x | -1.7 % | 654.5 % |
